BioSpace News Archive

Shanghai Zhimeng Biopharma, Inc., announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener, developed for the treatment of refractory epilepsy.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced financial results for the three months ended March 31, 2022.

Coherent, Inc. (NASDAQ, COHR), one of the world’s leading providers of lasers, laser-based technologies and laser-based system solutions in a broad range of scientific, commercial and industrial applications, today announced financial results for its second fiscal quarter ended April 2, 2022.

Regulatory News: NANOBIOTIX, a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the following conferences.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the first quarter of 2022.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Spinal Machined Bone Allograft Market Size 2022-2028- Increasing Incidence Of Spinal Injuries In Elderly Individuals And Arthritis Patients, Advancement In Technology, And Rise In The Number Of Spine Surgeries Across The World Are Key Factors of Market Growth

The industry analysis report is considered a valuable source of information about the global Sperm Separation Method industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the Guggenheim Securities Radiopharmaceuticals Day in New York, New York on Tuesday, May 17, 2022 at 3:00 p.m. ET.

Travere Therapeutics, Inc. announced that on May 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 91,000 shares of its common stock.